Sci Rep:前列腺癌中黄酮体受体研究

2018-08-07 AlexYang MedSci原创

类固醇激素在前列腺中的致癌作用可以由它对前列腺癌(PCa)中的雄激素阻断治疗的影响来进行部分的解释。类固醇激素家族的其他成员,比如黄酮体,同样在PCa中具有一定的作用,但是黄酮体的作用仍旧没有明确的鉴定。最近,有研究人员调查了黄酮体受体亚型(PGRA和PGRB)在PCa组织中的分布,并调查了它们与临床终点的相关性。研究人员通过搜集535名患者的根治性前列腺切除样本进行了回顾性的研究,并利用组织芯片

类固醇激素在前列腺中的致癌作用可以由它对前列腺癌(PCa)中的雄激素阻断治疗的影响来进行部分的解释。类固醇激素家族的其他成员,比如黄酮体,同样在PCa中具有一定的作用,但是黄酮体的作用仍旧没有明确的鉴定。

最近,有研究人员调查了黄酮体受体亚型(PGRA和PGRB)在PCa组织中的分布,并调查了它们与临床终点的相关性。研究人员通过搜集535名患者的根治性前列腺切除样本进行了回顾性的研究,并利用组织芯片对那些精心筛选的代表性肿瘤区域组织进行了分析。另外,研究人员还利用免疫组化技术在基质的上皮组织中,对蛋白的表达进行了评估,并利用生存统计分析对受体表达和临床数据进行了相关性分析。研究发现,PGRA-只在机制中表达,而PGRB在基质中和上皮中均表达。进一步的是,单变量分析和多变量分析均表明PGRB在肿瘤组织中的高表达与不良的预后相关:生化失败(HR: 2.0, 95% CI: 1.45-2.76, p<0.001)和临床失败(HR: 2.5, 95% CI: 1.29-4.85, p=0.006)。

最后,研究人员指出,他们的发现与之前的pan-PGR调查结果一致,表明了观察到的PGR副作用可以由PGRB代表。

原始出处:

Thea Grindstad, Elin Richardsen, Sigve Andersen et al. Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression. Sci Rep. 27 July 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1683582, encodeId=364716835820a, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Fri Mar 22 19:59:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340144, encodeId=d8f3340144ca, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Wed Aug 22 13:05:17 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338222, encodeId=b29a3382225d, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:18:40 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337707, encodeId=3f8a33e707d5, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 10 13:46:16 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337304, encodeId=583733e304e7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Aug 08 12:50:17 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2019-03-22 fengyi821
  2. [GetPortalCommentsPageByObjectIdResponse(id=1683582, encodeId=364716835820a, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Fri Mar 22 19:59:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340144, encodeId=d8f3340144ca, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Wed Aug 22 13:05:17 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338222, encodeId=b29a3382225d, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:18:40 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337707, encodeId=3f8a33e707d5, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 10 13:46:16 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337304, encodeId=583733e304e7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Aug 08 12:50:17 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-22 AlexYang

    好文章!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1683582, encodeId=364716835820a, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Fri Mar 22 19:59:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340144, encodeId=d8f3340144ca, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Wed Aug 22 13:05:17 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338222, encodeId=b29a3382225d, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:18:40 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337707, encodeId=3f8a33e707d5, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 10 13:46:16 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337304, encodeId=583733e304e7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Aug 08 12:50:17 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-13 kafei

    学习了谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1683582, encodeId=364716835820a, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Fri Mar 22 19:59:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340144, encodeId=d8f3340144ca, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Wed Aug 22 13:05:17 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338222, encodeId=b29a3382225d, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:18:40 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337707, encodeId=3f8a33e707d5, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 10 13:46:16 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337304, encodeId=583733e304e7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Aug 08 12:50:17 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-10 liumin1987

    ***

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1683582, encodeId=364716835820a, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Fri Mar 22 19:59:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340144, encodeId=d8f3340144ca, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Wed Aug 22 13:05:17 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338222, encodeId=b29a3382225d, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:18:40 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337707, encodeId=3f8a33e707d5, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 10 13:46:16 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337304, encodeId=583733e304e7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Aug 08 12:50:17 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-08 一个字-牛

    学习了谢谢分享

    0

相关资讯

Prostate Cancer P D :积极监控群体中的前列腺癌与MRI

多参数核磁共振成像(mpMRI)在前列腺癌的积极监测(AS)中使用越来越多。最近,有研究人员调查了关于AS的病灶mpMRI表现的变化,来表明可视病灶体积测量的可变性,从而跟君等级评估病灶大小的变化情况。研究人员回顾性的检索了86名AS的男性,并且经历了不少于1次mpMRI(第一次在2013年前)。2名放射科专家均对患者参数和扫描时间处于不知状态。他们对扫描进行随机的报告来减少偏差。对可视的病灶,研

N Engl J Med:恩杂鲁胺有效延缓未转移前列腺癌病情进展

对于那些未转移的去势抵抗性前列腺癌患者来说,如果出现PSA的迅速升高,则很可能预示着患者存在较高的转移风险,前期的研究已经证实,恩杂鲁胺可以延长转移性去势抵抗性前列腺癌患者的总体生存期,那么它是否能够同样有效于未转移的去势抵抗性前列腺癌呢?其对延缓此类患者的肿瘤转移时间和PSA升高情况能否起到更多的帮助呢?近日,Maha Hussain等人报道了他们关于此方面的临床研究[1],为此类病人的化疗

盘点:2018年度J Clin Oncol杂志前列腺癌相关进展汇总(一)

【盘点】2018年度J Clin Oncol杂志前列腺癌相关进展汇总(一)

Cell Physiol Biochem:前列腺癌风险与MicroRNAs(Rs11614913, Rs2910164, Rs3746444)3个遗传变异相关性

MicroRNAs(miRNAs)是一类小的非编码RNA分子,并且在转录和翻译调控中具有重要的作用。在已经公布的数据中,关于miRNA SNPs与前列腺癌风险之间相关性还没有明确的结论。研究人员对所有可利用的研究资料进行了元分析,包括了2227名患者和2331名对照,从而来评估3个常见的miRNAs遗传变异位点对前列腺癌风险的影响。让步比(ORs)和95%置信区间(CIs)则用来调查相关性的强度。

CLIN CANCER RES:接受阿比特龙治疗的前列腺癌游离DNA改变情况

阿比特龙是治疗转移性趋势抵抗前列腺癌的常见药物。但是约20%到40%的患者会出现阿比特龙耐药。CLIN CANCER RES近期发表了一篇文章,寻找阿比特龙治疗反应的预测性分子标志,研究与治疗耐药相关的机制。

EMA限制使用前列腺癌药物Xofigo

欧洲药品管理局(EMA)已完成对癌症药物Xofigo(镭-223二氯化物)的审查,并建议限制其用于曾经接受过两次转移性前列腺癌治疗的患者(前列腺癌已经扩散到骨骼中)。